Across TCGA pan-cancer cohorts, RWDD4P2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RWDD4P2 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher RWDD4P2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RWDD4P2 expression acts as an unfavorable survival marker.
KIRP, BLCA, and SKCM are the cancer types where RWDD4P2 Mutation most reproducibly stratifies survival.